Literature DB >> 19109395

Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination.

Wing-Pui Kong1, Lan Wu, Timothy C Wallstrom, Will Fischer, Zhi-Yong Yang, Sung-Youl Ko, Norman L Letvin, Barton F Haynes, Beatrice H Hahn, Bette Korber, Gary J Nabel.   

Abstract

An effective AIDS vaccine must control highly diverse circulating strains of human immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) protein contains variable as well as conserved regions. In this report, an informatic approach to the design of T-cell vaccines directed to HIV-1 Env M group global sequences was tested. Synthetic Env antigens were designed to express mosaics that maximize the inclusion of common potential T-cell epitope (PTE) 9-mers and minimize the inclusion of rare epitopes likely to elicit strain-specific responses. DNA vaccines were evaluated using intracellular cytokine staining in inbred mice with a standardized panel of highly conserved 15-mer PTE peptides. One-, two-, and three-mosaic sets that increased theoretical epitope coverage were developed. The breadth and magnitude of T-cell immunity stimulated by these vaccines were compared to those for natural strain Envs; additional comparisons were performed on mutant Envs, including gp160 or gp145 with or without V regions and gp41 deletions. Among them, the two- or three-mosaic Env sets elicited the optimal CD4 and CD8 responses. These responses were most evident in CD8 T cells; the three-mosaic set elicited responses to an average of eight peptide pools, compared to two pools for a set of three natural Envs. Synthetic mosaic HIV-1 antigens can therefore induce T-cell responses with expanded breadth and may facilitate the development of effective T-cell-based HIV-1 vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109395      PMCID: PMC2643734          DOI: 10.1128/JVI.02256-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Evolutionary and immunological implications of contemporary HIV-1 variation.

Authors:  B Korber; B Gaschen; K Yusim; R Thakallapally; C Kesmir; V Detours
Journal:  Br Med Bull       Date:  2001       Impact factor: 4.291

2.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

Authors:  V Novitsky; U R Smith; P Gilbert; M F McLane; P Chigwedere; C Williamson; T Ndung'u; I Klein; S Y Chang; T Peter; I Thior; B T Foley; S Gaolekwe; N Rybak; S Gaseitsiwe; F Vannberg; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.

Authors:  Michael S Seaman; Ling Xu; Kristin Beaudry; Kristi L Martin; Margaret H Beddall; Ayako Miura; Anna Sambor; Bimal K Chakrabarti; Yue Huang; Robert Bailer; Richard A Koup; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

6.  The prevalence of antiretroviral drug resistance in the United States.

Authors:  Douglas D Richman; Sally C Morton; Terri Wrin; Nicholas Hellmann; Sandra Berry; Martin F Shapiro; Samuel A Bozzette
Journal:  AIDS       Date:  2004-07-02       Impact factor: 4.177

Review 7.  Diversity considerations in HIV-1 vaccine selection.

Authors:  Brian Gaschen; Jesse Taylor; Karina Yusim; Brian Foley; Feng Gao; Dorothy Lang; Vladimir Novitsky; Barton Haynes; Beatrice H Hahn; Tanmoy Bhattacharya; Bette Korber
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

8.  Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.

Authors:  Wing-Pui Kong; Yue Huang; Zhi-Yong Yang; Bimal K Chakrabarti; Zoe Moodie; Gary J Nabel
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

9.  Macaques vaccinated with live-attenuated SIV control replication of heterologous virus.

Authors:  Matthew R Reynolds; Andrea M Weiler; Kim L Weisgrau; Shari M Piaskowski; Jessica R Furlott; Jason T Weinfurter; Masahiko Kaizu; Taeko Soma; Enrique J León; Caitlin MacNair; Dan P Leaman; Michael B Zwick; Emma Gostick; Solomon K Musani; David A Price; Thomas C Friedrich; Eva G Rakasz; Nancy A Wilson; Adrian B McDermott; Rosanne Boyle; David B Allison; Dennis R Burton; Wayne C Koff; David I Watkins
Journal:  J Exp Med       Date:  2008-10-06       Impact factor: 14.307

10.  Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.

Authors:  Tetsuro Matano; Masahiro Kobayashi; Hiroko Igarashi; Akiko Takeda; Hiromi Nakamura; Munehide Kano; Chie Sugimoto; Kazuyasu Mori; Akihiro Iida; Takahiro Hirata; Mamoru Hasegawa; Takae Yuasa; Masaaki Miyazawa; Yumiko Takahashi; Michio Yasunami; Akinori Kimura; David H O'Connor; David I Watkins; Yoshiyuki Nagai
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

View more
  36 in total

1.  For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection.

Authors:  Ma Luo; Christina A Daniuk; Tamsir O Diallo; Rupert E Capina; Joshua Kimani; Charles Wachihi; Makubo Kimani; Thomas Bielawny; Trevor Peterson; Mark G R Mendoza; Sandra Kiazyk; T Blake Ball; Francis A Plummer
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  Novel adenovirus vector-based vaccines for HIV-1.

Authors:  Dan H Barouch
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 3.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

Review 4.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

5.  Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.

Authors:  E A Weaver; Z T Camacho; F Gao
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

6.  Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains.

Authors:  Karina Yusim; Rebecca Dilan; Erica Borducchi; Kelly Stanley; Elena Giorgi; William Fischer; James Theiler; Joseph Marcotrigiano; Bette Korber; Dan H Barouch
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

Review 7.  HIV-1 vaccine development after STEP.

Authors:  Dan H Barouch; Bette Korber
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

8.  Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.

Authors:  Dan H Barouch; Kara L O'Brien; Nathaniel L Simmons; Sharon L King; Peter Abbink; Lori F Maxfield; Ying-Hua Sun; Annalena La Porte; Ambryice M Riggs; Diana M Lynch; Sarah L Clark; Katherine Backus; James R Perry; Michael S Seaman; Angela Carville; Keith G Mansfield; James J Szinger; Will Fischer; Mark Muldoon; Bette Korber
Journal:  Nat Med       Date:  2010-02-21       Impact factor: 53.440

9.  Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.

Authors:  Sampa Santra; Hua-Xin Liao; Ruijin Zhang; Mark Muldoon; Sydeaka Watson; Will Fischer; James Theiler; James Szinger; Harikrishnan Balachandran; Adam Buzby; David Quinn; Robert J Parks; Chun-Yen Tsao; Angela Carville; Keith G Mansfield; George N Pavlakis; Barbara K Felber; Barton F Haynes; Bette T Korber; Norman L Letvin
Journal:  Nat Med       Date:  2010-02-21       Impact factor: 53.440

10.  Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.

Authors:  Anju Bansal; Tiffanie Mann; Sarah Sterrett; Binghao J Peng; Anne Bet; Jonathan M Carlson; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.